Financings Of The Fortnight: Movetis Files First European Biopharma IPO Since Early 2008
This article was originally published in The Pink Sheet Daily
Executive Summary
Notable biotech financings in November also include ThromboGenics, NicOx: 4SC AG, and Fate Therapeutics.
You may also be interested in...
Zealand Pharma Will Test European IPO Market
The Danish biotech hopes to tempt investors with revenue prospects from its late-stage GLP-1 analog, partnered with Sanofi-Aventis.
Zealand Pharma Will Test European IPO Market
The Danish biotech hopes to tempt investors with revenue prospects from its late-stage GLP-1 analog, partnered with Sanofi-Aventis.
Shire Emphasizes The GI Space In Its Bid For Movetis
Only five years ago, Shire's specialty pharma business consisted of one product, Adderall XR, one market, the U.S., and one patient type - children. Multiple generics companies had filed ANDAs, however, and the company was looking to broaden its base